TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05515003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized patient education
Description: In the intervention group, patients will undergo a single, personalized education session led by the researcher, lasting 30 to 60 minutes. Identified knowledge gaps will be addressed through focused education, followed by interactive question-and-answer sessions covering fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise, and sleep.~Follow-up calls will be conducted in the 1st, 2nd, and 3rd weeks post-education to monitor patient progress. Each call will assess general health status, symptom severity, and changes in bowel habits. Patients will be encouraged to review educational materials and ask questions, with appointment reminders provided during the 3rd week. These calls will each last approximately 10-15 minutes.~One month later, follow-up interviews will evaluate the education's impact using updated data collection tools, ensuring a thorough assessment of its effect on patient outcomes.
Study: NCT01599156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
Study: NCT03363243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOP Therapy Treatment group
Description: Testing of the STOP Therapy protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU) group
Description: Treatment as usual in the community through group therapy
Study: NCT00768794

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acidophilus
Description: Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acidolphilus
Description: The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
Study: NCT00600678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)
Description: Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
Study: NCT03354091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Flex 2
Description: Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
Study: NCT00757588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin, 5 mg + insulin
Description: Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + insulin
Description: Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
Study: NCT02703051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Infusion
Study: NCT00241228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venovenous haemofiltration (renal replacement therapy)
Description: High Volume ultra filtration (70 ml/kg/h)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venovenous haemofiltration (renal replacement therapy)
Description: Conventional Volume (35 ml/kg/h)
Study: NCT02307708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8° incline shoe
Description: Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesitherapy
Description: Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
Study: NCT04273334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NEB
Description: 68Ga-NEB were injected into the patients before the PET/CT scans
Study: NCT02885688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Nutrition
Description: Participants receive liquid nutrition by vein non-stop for up to 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin Drip
Description: Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin Drip
Description: Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU.
Study: NCT02643108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral episiotomy
Description: When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
Study: NCT04480320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pericapsular nerve group block
Description: Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
Study: NCT02995356

Intervention type: OTHER
Intervention: Collecting cervical liquid and sera samples

Intervention type: OTHER
Intervention: Collecting cervical liquid and sera samples
Study: NCT04376307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal flow anesthesia
Description: Investigators will use minimal flow anesthesia (0,5 lt/min) during surgery with one lung ventilation
Study: NCT03803189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care plus eToolkit
Description: The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS\<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
Study: NCT01152658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NACL
Description: Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
Study: NCT02872116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study: NCT04349072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Mavacamten Capsules Other names: MYK-461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05189743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin transplantation to heal burn injuries
Description: The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin transplantation to heal burn injuries
Description: The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest.
Study: NCT04131023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breezing Metabolic Rate Tracking
Description: Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
Study: NCT01101399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
Study: NCT04389359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG
Description: Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.
Study: NCT02898454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Pharmaceutical form: Suspension~Route of administration: Intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Pharmaceutical form: Suspension~Route of administration: Intranasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Pharmaceutical form: Suspension~Route of administration: Intranasal
Study: NCT02735967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: diadynamic current
Description: Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diadynamic current
Description: Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
Study: NCT00148902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel
Study: NCT01256268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
Study: NCT02952365

Intervention type: DRUG
Group type: OTHER
Intervention: Tissue sealant
Description: Application of tissue sealant on eyes undergoing LASIK enhancement
Study: NCT03844399

Intervention type: DEVICE
Intervention: Ablation
Description: The medical device will passively record image data during the standard care ablation

Intervention type: DEVICE
Intervention: Biopsy
Description: The medical device will passively record image data during the standard care biopsy
Study: NCT01283555

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir
Description: Delivered using prefilled and user-filled applicator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Delivered using prefilled and user-filled applicator
Study: NCT02657889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study: NCT00392392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: ABI-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab
Study: NCT01820286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recollection intervention
Study: NCT02416999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-low dose Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT04604041

Intervention type: DIAGNOSTIC_TEST
Intervention: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA
Description: All groups will not have the same intervention. Interventions are listed and numbered for each group.

Intervention type: DIAGNOSTIC_TEST
Intervention: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA
Description: All groups will not have the same intervention. Interventions are listed and numbered for each group.

Intervention type: DIAGNOSTIC_TEST
Intervention: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA
Description: All groups will not have the same intervention. Interventions are listed and numbered for each group.
Study: NCT00788307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-CMV-NIS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liothyronine sodium

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131
Study: NCT01894607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Intraoperative Ultrasound
Description: During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY
Description: During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
Study: NCT00849940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAS NIRS FORE-SIGHT oximeter
Description: Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
Study: NCT00629044

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessing the blood level of cholesterol 24 S Hydroxylase
Description: Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessing the blood level of cholesterol 24 S hydroxylase
Description: Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: assessing the blood level of cholesterol 24 S hydroxylase
Description: Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects